Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1 18Phase 1/2 9Phase 3 6Phase NA 3Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 38Unknown 9Terminated 8Recruiting 6Withdrawn 3Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Rituximab 4Lenalidomide 4zanubrutinib 1orelabrutinib 1obinutuzumab 1Vincristine 1Radiation 1Prednisone 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Lymphoma, B-Cell, Marginal Zone × Clear all
NCT05100862 2026-05-27

MAHOGANY

BeOne Medicines

Phase 3 Recruiting
780 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06149286 2026-05-06

OLYMPIA-5

Regeneron Pharmaceuticals

Phase 3 Recruiting
470 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT07029217 2026-02-17

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 3 Recruiting
375 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Recruiting
260 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06082102 2025-09-15

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3 Recruiting
324 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04834024 2024-11-20

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Beijing Mabworks Biotech Co., Ltd.

Phase 3 Recruiting
168 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡